PTO/SB/08a (03-09)
Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/593,059 - Conf. No. 7239	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	September 15, 2006	
ST	ATEMENT	BY A	PPLICANT	First Named Inventor	Shimon Weiss	
				Art Unit	1634	
	(Use as many she ets as necess ary)			Examiner Name	Frank Wei Min Lu	
Sheet	1	of	2	Attorney Docket Number	58086-235410	

		U.S	. PATENT DOC	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	A1				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T°
	B1		:			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, j ournal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Boss, M.A., Kenten, J.H., Wood, C.R., and Emtage, J.S., Assembly of functional antibodies from immunoglobulin heavy and light chains synthesized in E. coli. Nucleic Acids Res. 1984 May 11;12(9):3791-806.	
	C2	Cabilly, S., Riggs, A. D., Pande, H., Shively, J. E., Holmes, W. E., Rey, M., Perry, L. J., Wetzel, R., and Heyneker, H. L., Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli, Proc. Natl. Acad. Sci., USA, 81:3273 - 3277, 1984.	
	СЗ	Feldhaus, M.J., Siegel, R.W., Opresko, L.K., Coleman, J.R., Feldhaus, J.M., Yeung, Y.A., Cochran, J.R., Heinzelman, P., Colby, D., Swers, J., Graff, C., Wiley, H.S., Wittrup, K.D., Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library., Nat Biotechnol. 21:163-70, 2003	
	C4	Fendly, B.M., Kotts, C., Vetterlein, D., Lewis, G.D., Winger, M., Carver, M.E., Watson, S.R., Sarup, J., Saks, S., Ullrich, A., et al., The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer, J Biol Response Mod. 9:449-55, 1990	
	C5	Hammarstrom, S., J. E. Shively, et al. (1989). "Antigenic sites in carcinoembryonic antigen." Canc.Res. 49: 4852-4858.	
	C6	Hanes, J., L. Jermutus, et al. (1998). "Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries." Proc.Natl.Acad.Sci.USA 95: 14130-14135.	
	C 7	Hellstrom, I., Garrigues, H.J., Garrigues, U., Hellstrom, K.E., Higfily tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens, Cancer Res. 50:2183-90, 1990.	
	C8	Huston, J. S., D. Levinson, et al. (1988). "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli." Proc.Natl.Acad.Sci.USA 85: 5879-5883.	
	C9	Korlach, J., Baird, D.W., Heikal, A. A., Gee, K. R., Hoffman, G. R., and Webb, W.W., Spontaneous nucleotide exchange in low molecular weight GTPases by fluorescently labeled {gamma}-phosphate-linked GTP analogs, Proc. Natl. Acad. Sci. USA, 101(14), 5180, 2004.	
	C10	Marks, J. D., H. R. Hoogenboom, et al. (1991). "By-passing immunization: Human	

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/593,059 - Conf. No. 7239 INFORMATION DISCLOSURE Filing Date September 15, 2006 STATEMENT BY APPLICANT First Named Inventor **Shimon Weiss** 1634 Art Unit (Use as many she ets as necessary) Examiner Name Frank Wei Min Lu Sheet 2 2 58086-235410 of Attorney Docket Number

			
		antibodies from V-gene libraries displayed on phage." J.Mol.Biol. 222: 581-597.	
	C11	Marquart, M., Deisenhofer, J., Huber, R., Palm, W., Crystallographic refinement and atomic modelq of the intact immunoglobulin molecule Kol and its antigenbinding fragment at 3.0 A and 1.9 A resolution, J Mol Biol. 141:369-91, 1980	
	C12	Paulmurugan, R. and Gambhir, S.S., Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment —assisted complementation, Analytical Chemistry, 75: 1584-1589, 2003.	
	C13	Rossi, F., Charlton, C. A., Blau, H. M., Monitoring protein-protein interactions in intaqct eukaryotic cells by B-galactosidase complementation, Proc. Natl. Acad. Sci., 94: 8405-10, 1997.	
	C14	Satow, Y., Cohen, G.H., Padlan, E.A., Davies, D.R., Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A, J Mol Biol. 190:593-604, 1986	
	C15	Spotts, J.M., Dolmetsch, R. E., Greenberg, M.E., Time-lapse imaging of a dynamic phosphorylation-dependent protein-protein interaction in mammalian cells, Proc. Natl., Acad. Sci., 99(23): 15142-47, 2002.	
	C16	Wu, A.M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fisher, R., Hu, S-Z., Odom-Maryon, T., Wong, J. Y. C., and Shively, J. E. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers, Immunotechnology, 2: 21-36, 1996.	
	C17	Yates, S., Penning, M., Goudsmit, J., Frantzen, I., Weijer, B., Strijp, D., Gemen, B., Quantitative detection of Hepatitis B virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection, J. Clin. Micro., 39(10): 3656-65, 2001.	
	C18	Yao, G., Fang, X., Yokota, H., Yanagida, T., Tan, W., Monitoring molecular beacon DNA probe hybridization at the single molecule level, Chem. Eur. J., 9: 5686-92, 2003.	
	C19	Yokota, T., Milenic, E. D., Whitlow, M. and Schlom, J., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Research, 52: 3402-3408, 1992.	
	C20	You, Y. H., L. J. Hefta, et al. (1998). "Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in Pichia Pastoris. The essential role of the N-domain." Anticancer Res. 18: 3193-3202, 1998.	
		1	JL

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.